Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to: Investigate the Overall Response Rate (ORR) of the
combination of ofatumumab and bortezomib in patients with low-grade B-cell non-Hodgkin
lymphoma (LG-NHL) that relapse beyond 6 months of a previous rituximab-containing regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Brown University
Collaborators:
Dartmouth-Hitchcock Medical Center Memorial Hospital of Rhode Island Rhode Island Hospital The Miriam Hospital